Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments

HER2 positive breast cancer represent about 20% of all breast cancer subtypes and it was considered the subtype with the worst prognosis until the discovery of therapies directed against the HER2 protein. The determination of the status of the HER2 must be very precise and well managed to identify t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Serafin Morales, Ariadna Gasol, Douglas Rene Sanchez
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	HER2 positive breast cancer targeted therapies treatment algorithm Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c9eb8363730249bbb9b80027907b37e7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9eb8363730249bbb9b80027907b37e7
record_format	dspace
spelling	oai:doaj.org-article:c9eb8363730249bbb9b80027907b37e72021-11-25T17:03:50ZHer2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments10.3390/cancers132257712072-6694https://doaj.org/article/c9eb8363730249bbb9b80027907b37e72021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5771https://doaj.org/toc/2072-6694HER2 positive breast cancer represent about 20% of all breast cancer subtypes and it was considered the subtype with the worst prognosis until the discovery of therapies directed against the HER2 protein. The determination of the status of the HER2 must be very precise and well managed to identify this subtype, and there are very specific and updated guides that allow its characterization to be adjusted. Treatment in local disease has been considerably improved with less aggressive and highly effective approaches and very high cure rates. In metastatic disease, average median survival rates of 5 years have been achieved. New highly active molecules have also been discovered that allow disease control in very complicated situations. This article reviews all these options that can be used for the management of this disease.Serafin MoralesAriadna GasolDouglas Rene SanchezMDPI AGarticleHER2 positive breast cancertargeted therapiestreatment algorithmNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5771, p 5771 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	HER2 positive breast cancer targeted therapies treatment algorithm Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	HER2 positive breast cancer targeted therapies treatment algorithm Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Serafin Morales Ariadna Gasol Douglas Rene Sanchez Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
description	HER2 positive breast cancer represent about 20% of all breast cancer subtypes and it was considered the subtype with the worst prognosis until the discovery of therapies directed against the HER2 protein. The determination of the status of the HER2 must be very precise and well managed to identify this subtype, and there are very specific and updated guides that allow its characterization to be adjusted. Treatment in local disease has been considerably improved with less aggressive and highly effective approaches and very high cure rates. In metastatic disease, average median survival rates of 5 years have been achieved. New highly active molecules have also been discovered that allow disease control in very complicated situations. This article reviews all these options that can be used for the management of this disease.
format	article
author	Serafin Morales Ariadna Gasol Douglas Rene Sanchez
author_facet	Serafin Morales Ariadna Gasol Douglas Rene Sanchez
author_sort	Serafin Morales
title	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
title_short	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
title_full	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
title_fullStr	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
title_full_unstemmed	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
title_sort	her2-positive cancers and antibody-based treatment: state of the art and future developments
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c9eb8363730249bbb9b80027907b37e7
work_keys_str_mv	AT serafinmorales her2positivecancersandantibodybasedtreatmentstateoftheartandfuturedevelopments AT ariadnagasol her2positivecancersandantibodybasedtreatmentstateoftheartandfuturedevelopments AT douglasrenesanchez her2positivecancersandantibodybasedtreatmentstateoftheartandfuturedevelopments
_version_	1718412803235119104

Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments

Ejemplares similares